HIMS & HOS (HIMS) T2 Gains 2025

Actions of Hims & His Health dropped 9% in prolonged exchanges on Monday after the Télésanté company announced results of the second quarter which missed Wall Street in terms of income.

Here is how the company did according to the average estimates of analysts compiled by LSEG:

• Profit by action: 17 cents adjusted vs 15 cents expected
• Income: $ 544.8 million against $ 552 million expected

Income from Hims & Hers increased by 73% in the second quarter, compared to $ 315.6 million during the same period last year, according to a statement. Hims & Hers declared a net profit of $ 42.5 million, or 17 cents per share, against $ 13.3 million, or 6 cents per share, during the same period a year earlier.

For his third quarter, Hims & Hers said he expected income between $ 570 million and $ 590 million, while analysts were waiting for $ 583 million. The company said its profits adjusted before interest, taxes, depreciation and damping, or Ebitda, for the quarter will be between $ 60 million and $ 70 million. Analysts interviewed by Streetaccount awaited $ 77.1 million.

Hims & Hers has been faced with controversy in recent months during its continuous sale of compounds GLP-1, which are cheaper and not approved versions of successful diabetes and weight loss drugs. Compound drugs can be mass produced when brand treatments are shortened, but the United States Food and Drug Administration announced in February that current supply problems had been resolved.

Certain TV companies, including Hims & Hers, have continued to offer compound medicines. It is legal for patients to access personalized doses imitations in unique cases, as if they are allergic to an ingredient in a brand product, for example. Hims & Hers said consumers may always be able to access personalized doses via its clinically applicable site.

In June, HIMS and HERS shares dropped more than 30% after short -term collaboration with Novo Nordisk Fallen in scales. The drug manufacturer said that Hims & Hers “had failed to respect the law which prohibits mass sales of compound drugs” under the “false appearance” of personalization.

Hims & Hers said an adjusted Ebitda of $ 82 million for its second quarter, compared to $ 39.3 million last year and more of the $ 73 million expected by Streetaccount.

Hims & Hers will organize its quarterly call with investors at 5 p.m. he.

– Annika Kim Constantino from CNBC contributed to this report.